Why the study?
Can a modified thromboelastograph (MTEG) detect inhibition of clot strength by c7E3 Fab and its reversal with platelet-rich plasma in anticoagulated blood from cardiac surgery patients?
Population
Anticoagulated blood samples from 17 patients scheduled for cardiac surgery
Design
Preclinical
Authors
Loading...
MTEG detects abciximab effects in vitro; leaves open clinical validation in cardiac surgery patients.
Can a modified thromboelastograph (MTEG) detect inhibition of clot strength by c7E3 Fab and its reversal with platelet-rich plasma in anticoagulated blood from cardiac surgery patients?
A modified thromboelastograph assay can effectively detect the dose-dependent inhibition of clot strength by c7E3 Fab (abciximab) and its reversal with platelet-rich plasma in vitro.
Greilich et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: